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Abstract
Background: During a dengue outbreak on the Caribbean island Aruba, highly elevated levels of ferritin were detected in
dengue virus infected patients. Ferritin is an acute-phase reactant and hyperferritinaemia is a hallmark of diseases caused by
extensive immune activation, such as haemophagocytic lymphohistiocytosis. The aim of this study was to investigate
whether hyperferritinaemia in dengue patients was associated with clinical markers of extensive immune activation and
coagulation disturbances.
Methodology/Principal Findings: Levels of ferritin, standard laboratory markers, sIL-2R, IL-18 and coagulation and
fibrinolytic markers were determined in samples from patients with uncomplicated dengue in Aruba. Levels of ferritin were
significantly increased in dengue patients compared to patients with other febrile illnesses. Moreover, levels of ferritin
associated significantly with the occurrence of viraemia. Hyperferritinaemia was also significantly associated with
thrombocytopenia, elevated liver enzymes and coagulation disturbances. The results were validated in a cohort of dengue
virus infected patients in Brazil. In this cohort levels of ferritin and cytokine profiles were determined. Increased levels of
ferritin in dengue virus infected patients in Brazil were associated with disease severity and a pro-inflammatory cytokine
profile.
Conclusions/Significance: Altogether, we provide evidence that ferritin can be used as a clinical marker to discriminate
between dengue and other febrile illnesses. The occurrence of hyperferritinaemia in dengue virus infected patients is
indicative for highly active disease resulting in immune activation and coagulation disturbances. Therefore, we recommend
that patients with hyperferritinaemia are monitored carefully.
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Introduction
Outbreaks of dengue virus (DENV) infection have become more
frequent in the American and Caribbean region, even threatening
to spread in the United States [1]. DENV is a flavivirus, which is
transmitted by the bite of an Aedes mosquito. Brazil is the
country with most reported dengue cases in the Americas. A large
DENV-2 outbreak in 2010 caused more than 34.000 cases and 64
deaths in the State of Sa˜o Paulo, Brazil [2]. On the Caribbean
island Aruba, there was an epidemic from September 2011 till
April 2012, in which DENV-1 and DENV-4 were both co-
circulating.
The symptoms of DENV infection are mild and self-limiting in
the majority of cases, consisting of fever, headache, retro-orbital
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pain, myalgia, arthralgia, thrombocytopenia, minor mucosal
bleeding and skin manifestations. Some patients develop severe
symptoms, such as shock, severe bleeding or organ impairment.
These symptoms usually develop three to five days after the onset
of disease around the time of defervescence. It has been
hypothesized that severe dengue is caused by a cytokine storm
inducing systemic inflammatory effects (Reviewed in [3]). The
pathophysiological mechanisms that cause this cytokine storm are
not fully unravelled and represent an important focus for dengue
research.
In addition to the current laboratory markers for dengue,
ferritin levels were described to be associated with clinical disease
severity in children [4]. In many cases ferritin levels higher than
500 mg/L were detected, defined as hyperferritinaemia [5].
Ferritin is an acute-phase reactant and highly expressed by cells
of the reticulo-endothelial system in response to infection and
inflammation. Ferritin binds iron, limiting its availability in the
circulation. Because many pathogenic microorganisms need iron
for their proliferation, this mechanism is favourable for the host.
Moreover, iron deficiency enhances the immunological perfor-
mance of lymphocytes, neutrophils and macrophages (reviewed in
[6]).
Hyperferritinaemia is a hallmark of diseases, characterized by
extensive immune activation, including haemophagocytic lym-
phohistiocytosis (HLH) and macrophage activation syndrome
(MAS). HLH can be congenital or triggered by an external
stimulus, such as malignancy or viral infection, including
dengue [7]. NK cells and CD8+ T lymphocytes are impaired
in their cytotoxic function in patients with HLH, which results
in reduced clearance of infected and antigen-presenting cells
from the circulation. This may lead to an exaggerated immune
response with proliferation of dendritic cells, tissue macrophages
and T-cells, contributing to a cytokine storm (reviewed in [8]).
The symptoms of HLH consist of ongoing fever, hepatospleno-
megaly, cytopenia (affecting more than 2 cell lineages),
hypofibrinogenaemia, hypertriglyceridaemia, hyperferritinae-
mia, increased levels of sIL-2R and coagulopathy (reviewed in
[5]).
Although clinical symptoms of DENV infection are usually
rather mild compared to HLH, some patients develop severe
symptoms. These are most probably caused by extensive immune
activation and show similarities with the clinical hallmarks of HLH
and MAS, suggesting similar pathophysiology.
The aim of this study was to investigate the association between
hyperferritinaemia, immune activation and coagulation distur-
bances in DENV infected patients. We showed that the presence
of hyperferritinaemia could discriminate between dengue and
other febrile diseases. Moreover, we found an association between
increased ferritin levels and severe clinical disease, thrombocyto-
penia, liver enzyme and coagulation disturbances and a pro-
inflammatory cytokine profile.
Materials and Methods
Cohort Aruba and Brazil
Ethics statement. The study in Aruba was approved by the
Institutional Review Board of the Dr. Horacio Oduber Hospitaal
in Aruba. The study in Brazil was approved by the Institutional
Review Board from Hospital das Clı´nicas, University of Sa˜o Paulo
(CAPPesq - Research Projects Ethics Committee) under protocol
0652/09. Patients in both studies were included after written
informed consent was obtained. In case of participants younger
than 18 years informed consent was obtained from their parent or
legal guardian. Clinical data and blood samples were anonymized
with a study number.
In Aruba, all patients of 16 years and older with a clinical
suspicion of dengue, presenting at the emergency room of the
Dr. Horacio Oduber Hospitaal and one clinical practice between
September 2011 and April 2012, were included. Pregnant
women and patients with no available data about clinical
symptoms were excluded. After obtaining informed consent, the
treating physician filled out a standard case report form (CRF).
Patients were admitted to the hospital when at least one of the
following symptoms was present: systolic blood pressure lower
than 90 mm Hg, diastolic blood pressure lower than 60 mmHg,
pulse rate higher than 100/min, signs of dehydration, platelet
count lower than 50.000 cells/mm3, increase in haematocrit
above 50%, or signs of mucosal bleeding. Patients were classified
according to the 2009 WHO dengue case classification [9,10].
Briefly, patients with fever and general symptoms were classified
as non-severe dengue without warning signs (WS2). Patients
with one of the following warning signs were classified as non-
severe dengue with warning signs (WS+): abdominal pain,
vomiting, minor mucosal bleeding, pleural effusion, ascites and
hepatomegaly. Patients with shock, respiratory distress, severe
bleeding and/or organ impairment were classified as severe
dengue.
Serum and plasma samples were drawn at day 2–3, 4–5 and 6–
8 and 28 days after the onset of fever. Samples not immediately
used, were stored at 280uC and shipped to The Netherlands on
dry ice. Repetitive freeze-thaw cycles were avoided. The samples
from day 28 were used as an autologous control group.
The clinical diagnosis of dengue was confirmed either by a
positive NS1 antigen test (‘Platelia’, Bio-Rad, France) at day 2–3
and/or a positive IgM enzyme-linked immunosorbent assay
(ELISA) (‘IgM Capture DxSelect’, Focus Diagnostics, USA) at
day 4–5 and/or an increase in IgG titre (‘IgG Capture DxSelect’,
Focus Diagnostics, USA) between the acute and convalescent
sample. Patients with a negative NS1, IgM and IgG in the acute
phase sample and a negative IgG in the convalescent sample were
diagnosed as Other Febrile Illness (OFI). If the IgG was positive in
the acute phase sample, but the convalescent sample was missing,
patients were considered inconclusive and excluded from this
analysis. Patients with a positive IgG in the sample from day 4–5
were considered as secondary DENV infection, while patients with
Author Summary
Ferritin is an acute-phase reactant and produced by
reticulo-endothelial cells in response to inflammation and
infection. In general, ferritin levels are increased in
inflammatory conditions, but in this study we found that
ferritin levels were much higher in dengue virus infected
patients than in patients with other febrile illnesses. This
indicates that ferritin could be used as a marker to
discriminate between dengue and other febrile diseases.
Moreover, the presence of hyperferritinaemia (ferritin
levels$500 mg/L) was associated with markers of immune
activation and coagulation disturbances and clinical
disease severity, suggesting that it could serve as a marker
of activity of disease. Clinical markers to determine the
presence and severity of dengue virus infection are
important for diagnostic and treatment purposes. Our
results indicate that increased ferritin levels could be used
to increase the likelihood on a positive dengue diagnosis.
Moreover, patients with hyperferritinaemia should be
monitored carefully, because they are at risk to develop
severe disease due to extensive immune activation.
Hyperferritinaemia in Dengue
PLOS Neglected Tropical Diseases | www.plosntds.org 2 October 2014 | Volume 8 | Issue 10 | e3214
a negative IgG in this sample were considered as a primary DENV
infection [11].
The cohort in Brazil was described previously [12]. Briefly,
during the 2010 DENV-2 outbreak, patients with clinical
suspected dengue fever presenting at the Ana Costa Hospital,
Santos, State of Sa˜o Paulo were included. Patients were diagnosed
with DENV infection by detection of DENV NS1 antigen and/or
IgM-specific antibodies using a commercially available rapid test
(Dengue Duo Test Bioeasy, Standard Diagnostic Inc. 575-34,
Korea) or by detection of DENV RNA by real time PCR (RT-
PCR). Serum samples were drawn and stored at 280uC. Patients
were classified according to the 2009 WHO classification and the
occurrence of haemorrhagic manifestations and the occurrence of
plasma leakage and shock [9,10]. Age-matched healthy volunteers
with a similar socio-economic background were used as controls.
Serotype- and copy number quantitative reverse
transcriptase PCR (RT-PCR) on serum samples from Aruba
In order to determine the infecting serotype a semi-quantitative
RT-PCR (Taqman) was performed. Primers and probes directed
against the capsid were derived from Sadon et al. [13]. Briefly, 46
TaqMan Fast Virus 1-step Master Mix (Invitrogen) was used with
20 pmol of primers and 10 pmol of probes. The cycling program
consisted of 5 minutes at 50uC, then 20 seconds at 95uC followed
by 40 cycles of 3 seconds at 95uC and 30 seconds at 60uC.
Another quantitative RT-PCR was performed to determine the
viral copy number. The primers and probes directed against the
39UTR were derived from Drosten et al. [14]. Briefly, 46
TaqMan Fast Virus 1-step Master Mix was used with 15 pmol of
primers and 10 pmol of probes and an additional 25 mM of
MgCl2 was added [15]. The cycling program was similar to the
serotype quantitative RT-PCR.
Ferritin and cytokines Aruba
Plasma ferritin concentrations were determined at the Land-
slaboratorium in Aruba within a few hours after blood sampling.
The assay was performed using the ‘Access’ (Beckman Coultier,
USA) under standardized conditions.
Serum sIL-2Ra and IL-18 levels were determined at the
department of experimental internal medicine from the Radboud
University. sIL-2Ra was measured using a commercially available
luminex kit (‘Milliplex’, Merck Millipore, Germany). Samples were
diluted 1:5 and the assay was performed according to the
manufacturer’s instructions and run on a Luminex 200 dual laser
detection system. The sensitivity limit was 15 pg/ml. Levels of IL-
18 were measured using a commercially available ELISA kit
(MBL, Japan) according to the manufacturer’s instructions.
Markers of coagulation Aruba
All markers of coagulation were determined in citrate samples.
Activated partial thromboplastin time (APTT) and prothrombin
time (PT) were determined at the Landslaboratorium in Aruba
within a few hours after blood withdrawal. PT (Dade Innovin) and
APTT (Dade Actin FSL) were determined on a Sysmex CA-1500
System (Siemens Healthcare Diagnostics, USA).
All other coagulation parameters were determined at the
department of Experimental Vascular Medicine from the
Academic Medical Centre. Von Willebrand Factor (vWF) was
measured using a home-made ELISA with antibodies from
DAKO (Glostrup, Denmark). In vitro thrombin generation was
assayed by measuring peak thrombin levels with the Calibrated
Automated Thrombography (CAT) as described previously [16].
In vivo thrombin generation was determined by detecting
thrombin-antithrombin complexes (TAT) using a commercially
available ELISA (Enzygnost). Levels of the fibrinolytic markers
plasminogen activator inhibitor type 1 (PAI-1) and plasmin-a2-
antiplasmin (PAP) complexes were measured with commercially
available ELISAs according to the manufacturer’s instructions
(PAI-1, Hyphen BioMed; PAP complexes, DRG Diagnostics). D-
dimer levels were determined with a particle-enhanced immuno-
turbidimetric assay (Innovance D-dimer, Siemens Healthcare
Diagnostics).
Ferritin and cytokine assays Brazil
Serum ferritin levels were determined with a commercially
available ELISA (Biolisa ferritina, Bioclin, Brazil) performed
according to the manufacturer’s instructions.
The measurement of cytokines and the cluster analysis have
been described in a previous publication [12]. Briefly, levels of
thirty cytokines were measured using a multiplex immunoassay kit
with spectrally encoded antibody-conjugated beads (Human
Cytokine 30-plex panel, Invitrogen, USA). Twenty-three cytokines
were used in a cluster analysis procedure, which was adapted from
van den Ham et al. [17]. Briefly, cytokine values were log-
transformed and subjected to hierarchical correlation clustering
(i.e., with distance measure 1 – pearson’s pairwise correlation
value) using Ward’s method.
Statistics
IBM SPSS Statistics v.20 was used to calculate statistical
significance. The Mann Whitney U test was used to compare the
difference between two groups. The Spearman’s correlation
coefficient was applied to calculate correlations. The Chi-
Squared test was used to calculate differences in proportions
between groups and the Fisher’s exact to determine whether one
distribution was unequally distributed over the groups. Using
bonferroni correction the p-value was adjusted for multiple
testing.
Results
Seventy-three patients were included in Aruba between
September 2011 and April 2012. The clinical diagnosis of forty-
four patients could be confirmed by serology and/or RT-PCR
(Table 1). Seventeen patients tested negative for DENV infection
and were included in the OFI group. Twelve patients were
excluded with an inconclusive diagnosis. In that particular season,
both DENV-1 and DENV-4 were circulating. One patient tested
positive for DENV-2, but this patient was probably infected in
Suriname. Moreover, 11 patients suffered from a primary and 30
patients from a secondary infection. In three patients the infection
status could not be determined.
The epidemic was rather mild and only one case of severe
dengue was recorded according to the 2009 WHO dengue case
classification. This patient presented with melaena and was
included in the WS+ group. From the other dengue positive
patients, seventeen were classified as WS2 and twenty-six as WS+
dengue. The most common warning sign was abdominal pain (20/
44, 45%) followed by vomiting (10/44, 23%) and in a few patients
epistaxis (2/44, 5%) and hepatomegaly (1/44, 2%) was reported.
Pleural effusion and ascites were not reported, probably because
ultrasound and/or X-ray examination were performed on a
limited basis. Fifteen dengue patients were admitted to the
hospital.
A total of 191 sequential samples from the forty-four patients
from Aruba were included in this analysis collected at day 2–8
after the onset of fever (sample size in Table S1). Follow-up
Hyperferritinaemia in Dengue
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samples collected at day 28 from dengue and OFI patients served
as an autologous control group.
Ferritin expression is associated with dengue virus
infection and viraemia
Ferritin levels were determined in patients with dengue and OFI
to identify any association with disease severity. Using the 2009
WHO dengue case classification, ferritin levels were significantly
increased in WS+ patients compared to OFI at each time point and
in WS2 patients compared to OFI at day 4–5 (Figure 1A). At day
4–5 and 6–8 the highest ferritin levels were observed and a tendency
was shown towards higher ferritin levels in WS+ patients compared
to WS2, although these differences were not statistically significant.
In clinical practice and according to the official HLH-criteria,
ferritin levels $500 mg/L are considered hyperferritinaemia [5]. A
larger proportion of males showed hyperferritinaemia compared
to females in this cohort, which approached statistical significance
(Table 1). It is known that baseline ferritin levels are higher in the
male than in the female population [18]. We calculated a fold
change by dividing the absolute values of ferritin by the median
ferritin levels for males and females from the autologous control
group (Females:/37 mg/L and males:/154 mg/L), which were
similar to levels previously described [18]. The ferritin fold change
was significantly increased in WS+ dengue patients compared to
OFI at each time point (Figure 1B).
Another marker of disease severity is the hospitalization rate.
Absolute levels and the ferritin fold change were significantly
increased in hospitalized and outpatients compared to OFI at
almost all time points (Figure 1C and 1D). The absolute ferritin
levels as well as the fold change showed a tendency of increased
values in hospitalized patients compared to outpatients.
Because the difference in ferritin levels between patients with
dengue and OFI was significant, we calculated an odds ratio for
the occurrence of hyperferritinaemia and a confirmed diagnosis of
DENV infection. In dengue patients, 19 out of 43 had
hyperferritinaemia compared to two out of 17 patients with
OFI. This resulted in a sensitivity of 44%, a specificity of 88% and
an odds ratio of 6. The high values of the specificity and odds ratio
suggest that the occurrence of hyperferritinaemia may serve as a
discriminatory marker between dengue and OFI.
The presence or absence of viraemia in the early phase was
linked to ferritin levels during the course of disease. Patients were
considered viraemic if they had detectable virus titres at day 2–3
and day 4–5. Patients with undetectable levels at these days were
considered non-viraemic.
The absolute ferritin levels were significantly elevated in
viraemic patients compared to non-viraemic patients at day 6–8
(Figure 2A). The ferritin fold change was significantly elevated in
viraemic patients at all time points (Figure 2B). There were no
strong correlations between the viral load and the levels of ferritin
at the same day of disease. However, absolute levels of ferritin at
day 6–8 correlated significantly with the viral copy number at day
2–3 (r= 0.5; P = 0.008) and day 4–5 (r= 0.5; P = 0.002) (Figure
S1). The ferritin fold change at day 6–8 also showed a significant
correlation with the viral load at day 2–3 (r= 0.5; P = 0.003) and
day 4–5 (r= 0.6; P,0.0001). This suggests that viral replication in
the early phase of disease may cause an increase in ferritin levels in
the convalescent phase.
Hyperferritinaemia in dengue is associated with
thrombocytopenia and elevated liver enzymes
Hyperferritinaemia is a prominent symptom of patients with
HLH. To investigate whether the clinical picture of DENV
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infection shows more similarities, the official diagnostic criteria for
HLH [5] were linked to hyperferritinaemia in dengue patients. In
each patient the occurrence of hyperferritinaemia was evaluated at
each time point.
Severe cytopenia in at least two cell lineages is a prominent
feature of HLH due to the increased phagocytic activity of
macrophages. In our cohort the platelet count was significantly
decreased in patients with hyperferritinaemia compared to
patients with no hyperferritinaemia and OFI at each time point
(Figure 3A, Table S2). No significant differences in the leukocyte
count were detected (Data not shown).
Another criterium is the presence of hypertriglyceridaemia and/
or hypofibrinogenaemia. Levels of fibrinogen were significantly
decreased in patients with hyperferritinaemia compared to patients
without hyperferritinaemia at day 6–8, but levels were still in the
range of the autologous control group (Figure 3B). The triglyceride
levels were in the normal range of the autologous control group in
both dengue as well as OFI patients (data not shown).
MAS is characterized by hepatosplenomegaly and liver
dysfunction. The liver also plays an important role in the
pathogenesis of DENV infection. Levels of the liver enzyme
ASAT were significantly increased in patients with hyperferriti-
naemia compared to patients with no hyperferritinaemia and OFI
at each time point (Figure 3C). ALAT levels were also significantly
increased in patients with hyperferritinaemia at day 4–5 and 6–8
(Figure 3D).
Figure 1. Ferritin levels and fold change are increased in dengue patients from Aruba. Absolute levels of ferritin were significantly
increased in WS+ patients compared to OFI at each time point and in WS2 patients compared to OFI at day 4–5 (A). Absolute levels were also
elevated in hospitalized and outpatients compared to OFI (C) at almost each time point. The ferritin fold change was significantly elevated in WS+
patients compared to OFI (B) and in hospitalized and outpatients compared to OFI (D) at each time point. Area between two dotted horizontal lines:
interquartile range from the autologous control group. Boxplots indicate the interquartile range, the horizontal line inside the box indicates the
median. The whiskers reach from the 10th till the 90th percentile. P-value#0.006 is considered significant.
doi:10.1371/journal.pntd.0003214.g001
Figure 2. Ferritin levels and fold change are associated with viraemia. The absolute ferritin levels were significantly increased in viraemic
patients compared to non-viraemic patients at day 6–8 (A) and the ferritin fold change was significantly elevated in viraemic patient at each time
point (B) in the cohort from Aruba. Area between two dotted horizontal lines: interquartile range from the autologous control group. Boxplots
indicate the interquartile range. The horizontal line inside the box indicates the median. The whiskers reach from the 10th till the 90th percentile. P-
value#0.02 is considered significant.
doi:10.1371/journal.pntd.0003214.g002
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sIL-2R is a marker of T-cell activation and IL-18 of
macrophage activation. sIL-2R was significantly increased in
patients with hyperferritinaemia compared to OFI at day 2–3
(Figure 3E). Levels of IL-18 were significantly elevated in patients
with no hyperferritinaemia compared to OFI at day 2–3 and in
patients with hyperferritinaemia compared to OFI at day 4–5
(Figure 3E). Altogether, we can conclude that hyperferritinaemia
in uncomplicated dengue patients is strongly associated with
thrombocytopenia and elevated liver enzymes, but these patients
had no hypertriglyceridaemia, hypofibrinogenaemia or cytopenia
in another lineage than the platelets.
Hyperferritinaemia is associated with activation of
coagulation and fibrinolysis
Hyperferritinaemia was investigated in association with param-
eters, indicating the activation of coagulation and fibrinolysis. The
APTT and PT showed no significant differences between any of
the groups (data not shown). vWF is released upon endothelial cell
activation and plays an important role in the formation of the
thrombus. Significantly increased levels were found in patients
with hyperferritinaemia compared to OFI at day 2–3 and in both
dengue groups compared to OFI at day 4–5 and 6–8 (Figure 4A).
Activation of the coagulation cascade starts with thrombin
Figure 3. Hyperferritinaemia is associated with certain markers of HLH and MAS. The platelet count (A) was significantly decreased and
the liver enzyme ASAT (C) significantly increased in patients with hyperferritinaemia compared to patients with no hyperferritinaemia and OFI at each
time point in the cohort from Aruba. Levels of fibrinogen were significantly decreased in patients with hyperferritinaemia compared to patients
without hyperferritinaemia at day 6–8 (B). Levels of ALAT were significantly increased in patients with hyperferritinaemia at day 4–5 and 6–8 (D).
Levels of sIL-2R were significantly increased in patients with hyperferritinaemia compared to OFI at day 2–3 (E). Levels of IL-18 were significantly
increased in patients with no hyperferritinaemia compared to OFI at day 2–3 and in patients with hyperferritinaemia compared to OFI at day 4–5 (F).
Missing values: Platelet count, ASAT, ALAT: no missing values. sIL-2R and IL-18: Day 2–3: No HF (N = 3), HF (N = 2). Day 4–5: No HF (N = 5), HF (N = 3).
Area between two dotted horizontal lines: interquartile range from the autologous control group. Boxplots indicate the interquartile range, the
horizontal line inside the box indicates the median. The whiskers reach from the 10th till the 90th percentile. P-value#0.006 is considered significant.
doi:10.1371/journal.pntd.0003214.g003
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generation after which it is bound by antithrombin. Thrombin-
antithrombin (TAT) complexes are a marker for activation of the
coagulation cascade in vivo. Levels were significantly elevated in
dengue patients with hyperferritinaemia compared to OFI at day
2–3 and 4–5 and also in patients without hyperferritinaemia
compared to OFI at day 4–5 (Figure 4B). The ability of plasma to
generate thrombin in vitro can be investigated by the calibrated
automated thrombrogram measuring peak thrombin levels.
Interestingly, while the levels of TAT were significantly increased,
the peak thrombin levels were significantly decreased in patients
with hyperferritinaemia compared to OFI at day 2–3 and 4–5
(Figure 4C). Thrombin generation will lead to fibrin formation
and eventually fibrinolysis, resulting in the formation of plasmin-
ogen-a2-antiplasmin (PAP) complexes. PAP showed increased
levels in patients with hyperferritinaemia compared to patients
with OFI at each time point (Figure 4D). Plasminogen activator
inhibitor-1 (PAI-1) can counteract the fibrinolytic system. Levels of
PAI-1 were significantly elevated in patients with hyperferritinae-
mia compared to OFI at day 4–5 (Figure 4E). Activation of the
coagulation and fibrinolytic systems eventually result in the
production of D-dimers (Figure 4F). Levels of D-dimers were
significantly increased in patients with hyperferritinaemia com-
pared to patients with no hyperferritinaemia and OFI at day 2–3
and levels were significantly elevated in patients with hyperferri-
tinaemia compared to OFI at day 4–5 and in patients without
hyperferritinaemia compared to OFI at day 6–8.
The coagulation and fibrinolytic systems are highly activated in
dengue patients and dengue patients with hyperferritinaemia in
particular. The strongest activation was shown at day 2–3 and 4–5
after onset of fever with increased levels of vWF, TAT, PAP and
D-dimer.
Ferritin levels in a Brazilian cohort are associated with
disease severity and immune activation
To confirm our findings concerning ferritin levels in the cohort
from Aruba, we studied ferritin in a previously published dengue
cohort obtained during the 2010 DENV outbreak in Brazil. This
cohort consisted of 50 WS2, 49 WS+ and 33 severe dengue
patients (More clinical details about this cohort are described in
the previous publication and in Tables S1,S3 and S4 [12]).
In this cohort the ferritin fold change was calculated with the
same formula as described for the cohort of Aruba, because the
autologous control group in Aruba was much larger (N = 45) than
the healthy control group in Brazil (N = 14). The ferritin fold
change was significantly elevated in patients with severe dengue
according to the 2009 WHO classification, as well as in patients
with shock and severe haemorrhage compared to patients with
uncomplicated dengue (Figure 5A, B and C). In non-survivors
levels were significantly elevated compared to survivors (Fig-
ure 5D). The absolute values of the ferritin fold change were on
average higher in the Brazilian than in the Aruba cohort. This
could be due to the presence of more severe disease in the cohort
from Brazil and the use of a different assay.
Patients were clustered based on the expression of the
determined cytokines as has been previously described
(Figure 5E and heatmap) [12]. Cluster A contained mainly
healthy controls, cluster B mild to moderately ill dengue patients
and cluster C contained severely ill dengue patients. Severe
dengue (P = 2.2610216), shock (3.461025), severe haemorrhage
(P = 0.007) and death (P = 0.03) occurred significantly more often
in cluster C than the other two clusters. Cluster C showed a pro-
inflammatory cytokine profile with increased expression of IL-6,
IL-8, IL-10, IL-15, IL-1RA, sIL-2R, HGF, VEGF, G-CSF, MCP-
1, IP-10, and MIG. Levels of ferritin were significantly increased in
cluster C compared to the other two clusters and levels were also
significantly elevated in the ‘dengue’ clusters B and C compared to
healthy control cluster A (Figure 5E). In summary, we can
conclude that levels of ferritin were significantly associated with
clinical disease severity and a pro-inflammatory cytokine profile.
Discussion
In the cohort from Aruba, increased concentrations of ferritin
were significantly associated with a confirmed dengue diagnosis
and viraemia. Moreover, hyperferritinaemia in dengue was
strongly associated with thrombocytopenia and increased levels
of liver enzymes and both activation of the coagulation and the
fibrinolytic systems. The findings were confirmed in a cohort from
Brazil, in which increased levels of ferritin were associated with
severe disease and a pro-inflammatory cytokine profile.
Ferritin is an acute-phase reactant and a significant amount is
produced by monocytes, macrophages and hepatic cells. It has
been shown that synthesis of ferritin can be induced by cytokines
and iron [19,20]. We showed that increased levels of ferritin were
associated with a pro-inflammatory cytokine profile. Lipopolysac-
charide (LPS) was shown to induce iron retention in human
monocytic cells, which may subsequently induce ferritin expres-
sion [21]. Interestingly, increased levels of LPS have been reported
in patients with dengue and were also associated with a pro-
inflammatory cytokine profile, suggesting that cytokines, LPS and
ferritin all play a role in immune activation in severe dengue
[12,22]. Interestingly, it has been shown in vitro that ferritin can
bind to high-molecular-weight kininogen and block the release of
bradykinin [23]. Bradykinin is a potent vasoactive agent and plays
an important role in the induction of vascular permeability and
even hypotension (reviewed in [24,25]). This may suggest that
ferritin during DENV infection is induced in an effort to protect
the host.
It is well known that infectious diseases in general cause
hyperferritinaemia (reviewed in [6]). We showed that even in
mild dengue, the occurrence of hyperferritinaemia could serve as
a discriminatory marker between dengue and other febrile
illnesses. Increased levels of cytokines and LPS have been
reported in several infectious diseases and therefore these
mechanisms cannot solely explain these extremely high ferritin
levels. Macrophages, monocytes and lymphocytes in the periph-
eral blood are the major target cells of DENV replication in vivo
[26,27]. Monocytes and macrophages are also important
producers of ferritin and therefore direct infection and subse-
quent viral replication in these cells may activate them and
increase the ferritin production. In agreement with this, ferritin
levels in the convalescent phase correlated strongly with the viral
load in the early phase. Interestingly, a high viral load in the early
phase of DENV infection has previously been associated with the
development of severe symptoms around the time of deferves-
cence [28].
Hepatocytes can also synthesize ferritin and in our study liver
enzymes were significantly elevated in patients with hyperferriti-
naemia. DENV replicates very well in hepatic cell lines in vitro,
but whether DENV replicates well in the liver in vivo is still a
matter of debate [26]. However, it is likely that liver cells are also
indirectly activated by cytokines and/or activated immune cells to
produce high amounts of ferritin. It has been shown that DENV
infection in mice resulted in NK and CD8+ T cell infiltration of
the liver [29].
HLH is characterized by extensive activation and proliferation
of NK and CD8+ T cells. CD8+ T-cells can be infected by DENV
in vitro [30]. Moreover, apoptosis of CD8+ T cells plays an
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important role in immune modulation during DENV infection
[31–33]. sIL-2R is a marker of T-cell activation and increased
levels of sIL-2R have been detected in dengue patients with severe
disease [28,34,35]. In a previous study with patients from the
Brazilian cohort, increased levels of sIL-2R were associated with
mortality [12]. In this study, using the same cohort, levels of
ferritin were also significantly associated with mortality, suggesting
that extensive activation of monocytes and macrophages with
subsequent T-cell activation may be detrimental for the host
during DENV infection.
Figure 4. Hyperferritinaemia is associated with markers of coagulation and fibrinolysis. Levels of vWF were significantly increased in
patients with hyperferritinaemia compared to OFI at each time point and significantly increased in patients without hyperferritinaemia compared to
OFI at day 4–5 and 6–8 (A) in the cohort from Aruba. Levels of TAT (B) were significantly increased and levels of peak thrombin (C) significantly
decreased in patients with hyperferritinaemia at day 2–3 and 4–5. Levels of PAP were significantly increased in patients with hyperferritinaemia
compared to OFI (D). Levels of PAI-1 were significantly increased in patients in patients with hyperferritinaemia compared to OFI at day 4–5 (E). Levels
of D-dimer were significantly increased in patients with hyperferritinaemia compared to OFI at day 2–3 and 4–5 and in patients with
hyperferritinaemia compared to patients without hyperferritinaemia at day 2–3 (F). Missing values vWF, PAI-1: Day 2–3: OFI (N = 1). Day 4–5: HF
(N = 1); TAT, PAP, D-dimer: No missing values; Peak thrombin: Day 2–3: No (N = 1), OFI (N = 1). Day 4–5: No (N = 1), HF (N = 4), OFI (N = 2). Day 6–8: No
(N = 2), HF (N = 1), OFI (N = 2). Area between two dotted horizontal lines: interquartile range from the autologous control group. Boxplots indicate the
interquartile range, the horizontal line inside the box indicates the median. The whiskers reach from the 10th till the 90th percentile. P-value#0.006 is
considered significant.
doi:10.1371/journal.pntd.0003214.g004
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Certain HLH-criteria, such as hypertriglyceridaemia, hypofi-
brinogenaemia and cytopenia in at least two cell lineages were not
found in this study, most probably because the patients in this
cohort only suffered from uncomplicated dengue. Increased
triglyceride levels and hypofibrinogenaemia have been reported
in patients with dengue shock syndrome and non-survivors
[36,37]. Therefore, we cannot exclude that HLH-like disease
occurs in dengue patients with severe symptoms.
In our study thrombocytopenia was strongly associated with
hyperferritinaemia. Thrombocytopenia is a hallmark of DENV
infection and it is hypothesized that it can be caused by binding of
platelets to activated endothelial cells [38]. Platelets are most
probably bound by vWF multimers, which were increased in
patients with hyperferritinaemia in this study. Because the
cytopenia was limited to the platelet count in DENV infection, it
is not very likely that phagocytosis by highly activated macro-
phages is the cause of thrombocytopenia as in the case of HLH.
Coagulopathy is one of the criteria of HLH and also described
in severe dengue (reviewed in [39]). In our cohort, the coagulation
and fibrinolytic systems were highly activated in patients with
hyperferritinaemia at day 2–3 and 4–5 after the onset of fever
resulting in increased levels of vWF, TAT, PAP and D-dimer.
Levels of TAT were increased in patients with hyperferritinaemia,
while levels of peak thrombin were decreased. TAT is a marker of
thrombin generation in vivo, while peak thrombin is a marker for
the potential of plasma to generate thrombin in vitro. From these
results we may conclude that coagulation activation, thrombin
formation and the consumption of coagulation factors decrease the
ex vivo capacity for clotting during DENV infection, which may
result in clinical bleeding symptoms. In addition to activation of
the coagulation cascade, increased levels of PAP, PAI-1 and D-
dimer showed that the fibrinolytic system was also highly activated
in patients with hyperferritinaemia.
Based on the collective results presented in the manuscript,
hyperferritinaemia can be considered as a clinical marker for
DENV infection, which can discriminate between dengue and
other febrile illness. Moreover, ferritin can also serve as a marker
for highly active disease resulting in extensive immune activation,
coagulation disturbances and severe clinical symptoms. Therefore,
we suggest that patients with hyperferritinaemia are monitored
carefully, as they are at higher odds to develop severe disease.
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Figure 5. Ferritin fold change is significantly associated with clinical disease severity and a pro-inflammatory cytokine profile in the
cohort from Brazil. The ferritin fold change was significantly elevated in patients with clinically severe disease as shown by classifying patients
according to the 2009 WHO classification (A), occurrence of plasma leakage and shock (B), occurrence of haemorrhage (C) and survival (D). Moreover,
levels were also significantly increased in Cluster C, which contains severely ill dengue patients with a pro-inflammatory cytokine profile (E).
Abbreviations: WS2= non-severe dengue without warning signs. WS+= non-severe dengue with warning signs. PL = plasma leakage. Area between
two dotted horizontal lines: interquartile range from the healthy control group (N = 14). Boxplots indicate the interquartile range, the horizontal line
inside the box indicates the median. The whiskers reach from the 10th till the 90th percentile. P-value#0.02 is considered significant. Heatmap: This
heatmap has been published previously [12]. A cluster analysis was performed with 23 cytokines, which resulted in a dendrogram indicated on the
left of the heatmap. Every horizontal line indicates one patients. The vertical bar on the left of the heatmap indicates the disease severity of the
patient. A: Cluster with mainly healthy controls and four dengue patients. B: Cluster with mild to moderately ill dengue virus infected patients. C:
Cluster with severely ill dengue virus infected patients. Abbreviations: 1: non-severe dengue without warning signs. 2: non-severe dengue with
warning signs. 3: severe dengue. +: patient died within 14 days after the onset of fever.
doi:10.1371/journal.pntd.0003214.g005
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